DelveInsight’s, “Basal Cell Nevus Syndrome Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Basal Cell Nevus Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Basal Cell Nevus Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ Basal Cell Nevus Syndrome Pipeline Outlook Report

Key Takeaways from the Basal Cell Nevus Syndrome Pipeline Report

• On 14 October 2025, Sol-Gel Technologies Ltd. conducted a clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
• DelveInsight’s Basal Cell Nevus Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Basal Cell Nevus Syndrome treatment.
• The leading Basal Cell Nevus Syndrome Companies such as Roche, PellePharm, Palvella Therapeutics and others.
• Promising Basal Cell Nevus Syndrome Therapies such as Patidegib, ASN-002, GDC-0449, Vismodegib, Aminolevulinic acid %20 topical solution, SUBA-Itraconazole, PTX-022, LDE225 and others.

Want to know which companies are leading innovation in Basal Cell Nevus Syndrome? Dive into the full pipeline insights @ Basal Cell Nevus Syndrome Clinical Trials Assessment

The Basal Cell Nevus Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Basal Cell Nevus Syndrome Pipeline Report also highlights the unmet needs with respect to the Basal Cell Nevus Syndrome.

Basal Cell Nevus Syndrome Overview

The nevoid basal cell carcinoma syndrome (NBCCS) is a rare, complex genetic disorder characterized by a wide variety of developmental abnormalities and a predisposition to developing certain forms of cancer, particularly a type of skin cancer known as basal cell carcinoma. The other names for BCNS include basal cell carcinoma nevus syndrome (BCCNS), Gorlin-Goltz syndrome, Gorlin syndrome, and nevoid basal cell carcinoma syndrome. These basal cell naevi are actually tiny basal cell carcinomas.

Basal Cell Nevus Syndrome Emerging Drugs

• Patidegib: PellePharm

PellePharm is focused on developing patidegib, an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. As of November 2018, PellePharm and LEO Pharma entered into a strategic collaboration to address the unmet medical needs for rare skin conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (HF-BCC). PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for Patidegib Topical Gel in Gorlin Syndrome from the FDA, as well as Orphan Drug Designation in Gorlin Syndrome from EMA’s Committee for Orphan Medicinal Products in the EU.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Basal cell nevus syndrome.

• Vismodegib: Roche

Vismodegib is an experimental, oral smoothened antagonist and thus inhibits hedgehog pathway. It is under Phase II development for Basal cell nevus syndrome.

If you’re tracking ongoing Basal Cell Nevus Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Basal Cell Nevus Syndrome Treatment Drugs

Basal Cell Nevus Syndrome Companies

Roche, PellePharm, Palvella Therapeutics and others.

The Basal Cell Nevus Syndrome Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Basal Cell Nevus Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Basal Cell Nevus Syndrome Treatment.
• Basal Cell Nevus Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Basal Cell Nevus Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Basal Cell Nevus Syndrome market.

Basal Cell Nevus Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Basal Cell Nevus Syndrome Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

From emerging drug candidates to competitive intelligence, the Basal Cell Nevus Syndrome Pipeline Report covers it all – check it out now @ Basal Cell Nevus Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Basal Cell Nevus Syndrome Pipeline Report

• Coverage- Global
• Basal Cell Nevus Syndrome Companies- Roche, PellePharm, Palvella Therapeutics and others.
• Basal Cell Nevus Syndrome Therapies- Patidegib, ASN-002, GDC-0449, Vismodegib, Aminolevulinic acid %20 topical solution, SUBA-Itraconazole, PTX-022, LDE225 and others.
• Basal Cell Nevus Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Basal Cell Nevus Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in oncology research – discover what’s next for the Basal Cell Nevus Syndrome Treatment landscape in this detailed analysis @ Basal Cell Nevus Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Basal Cell Nevus Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Patidegib: PellePharm
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Vismodegib: Roche
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Basal Cell Nevus Syndrome Key Companies
17. Basal Cell Nevus Syndrome Key Products
18. Basal Cell Nevus Syndrome- Unmet Needs
19. Basal Cell Nevus Syndrome- Market Drivers and Barriers
20. Basal Cell Nevus Syndrome- Future Perspectives and Conclusion
21. Basal Cell Nevus Syndrome Analyst Views
22. Basal Cell Nevus Syndrome Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/basal-cell-nevus-syndrome-bcns-pipeline-insight